Whereas all IgG1-treated (10/10) or IgE (12/12)-treated animals reached the human-defined endpoint by day 49, 50% (6/12) of IgG2a antibody–treated mice showed very small or no tumor growth at all, at day 60. This evidence concerns the gene IGHE and neoplasm.